EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • MSI-H/dMMR • BRAF mutation • NRAS mutation • RAS mutation • RET mutation • MET mutation

Lynparza (olaparib) • topotecan • Andewei (benmelstobart)

24d

TQB2450-II-14: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. (clinicaltrials.gov)

P2, N=71, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2024 --> Nov 2025 | Recruiting --> Terminated; Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.

24 days ago

Trial completion date • Trial termination • IO biomarker

carboplatin • gemcitabine • paclitaxel • docetaxel • Focus V (anlotinib) • doxorubicin hydrochloride • Andewei (benmelstobart)

Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs. (PubMed, Ther Adv Med Oncol)

We aimed to assess the efficacy, safety, and potential biomarkers of anlotinib plus TQB2450 in patients with advanced HCC. Elevated serum BDNF levels might serve as a potential positive prognostic marker and, together with ECOG score, may help complement the CRAFITY score in identifying subgroups that could benefit from ICIs and antiangiogenic therapy. This study was registered on ClinicalTrials.gov (NCT03825705, registered January 31, 2019).

1 month ago

Journal • PD(L)-1 Biomarker • IO biomarker

AFP (Alpha-fetoprotein) • BDNF (Brain Derived Neurotrophic Factor) • CRP (C-reactive protein)

Focus V (anlotinib) • Andewei (benmelstobart)

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC (clinicaltrials.gov)

P2, N=69, Not yet recruiting, Sun Yat-sen University

1 month ago

New P2 trial

KRAS (KRAS proto-oncogene GTPase)

Erbitux (cetuximab) • Focus V (anlotinib) • Andewei (benmelstobart) • Anfangning (garsorasib)

2ms

TQB2102-II-03: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality (clinicaltrials.gov)

P2, N=270, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Trial completion date: Feb 2026 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Jun 2026

2 months ago

Trial completion date • Trial primary completion date

Andewei (benmelstobart) • TQB2102

3ms

Combination Therapy with Hypofractionated Radiotherapy, GM-CSF, and Benmelstobart Followed by Bemzutizumab Plus Anlotinib Maintenance in Driver Mutation-Negative Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Who Failed Prior PD-1/PD-L1 Inhibitor Therapy: A Single-Arm Exploratory Study (ChiCTR2500108817)

P2, N=69, Not yet recruiting, The Second Affiliated Hospital of Nanjing Medical University; The Second Affiliated Hospital of Nanjing Medical University

3 months ago

New P2 trial • IO biomarker

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • ALK wild-type • ROS1 wild-type • EGFR negative

Focus V (anlotinib) • Andewei (benmelstobart)

3ms

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors (ChiCTR2500108531)

P2, N=60, Recruiting, The Second Affiliated Hospital of Shandong First Medical University; The Second Affiliated Hospital of Shandong First Medical University

3 months ago

New P2 trial

cisplatin • gemcitabine • Focus V (anlotinib) • Andewei (benmelstobart)

4ms

TQB2450 plus intensity-modulated radiotherapy in recurrent nasopharyngeal carcinoma: An open-label, single-arm, phase II trial. (PubMed, Med)

This combination therapy shows promising efficacy with a manageable safety profile in rNPC patients. Determination of MIF levels, tumor microenvironment characteristics, TCR profiling, and serial EBV DNA monitoring could identify patients who derive benefits from this therapeutic approach.

4 months ago

P2 data • Journal • PD(L)-1 Biomarker • IO biomarker

MIF (Macrophage Migration Inhibitory Factor)

Andewei (benmelstobart)

4ms

Anlotinib and Benmelstobart in DTC (clinicaltrials.gov)

P2, N=23, Not yet recruiting, Fudan University

4 months ago

New P2 trial

Focus V (anlotinib) • Andewei (benmelstobart)

4ms

Case Report: Synergistic multimodal therapy in SMARCA4-deficient undifferentiated tumor: integrating chemotherapy, anti-angiogenesis immunotherapy, and radiotherapy for enhanced outcomes. (PubMed, Front Oncol)

Sequential PET/CT imaging demonstrated metabolic regression of the primary tumor and metastatic lesions following chemotherapy combined with anti-angiogenic therapy (anlotinib) and PD-L1 inhibition (benmelstobart), followed by consolidative radiotherapy. This case highlights the potential of a mechanistic-driven, multimodal strategy to overcome therapeutic resistance in SMARCA4-deficient undifferentiated tumor. It underscores the need for further exploration of synergistic regimens in this molecular subset.

4 months ago

Journal

SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)

Focus V (anlotinib) • Andewei (benmelstobart)

5ms

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)

P2, N=165, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

5 months ago

New P2 trial • IO biomarker

cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • etoposide IV • Xpovio (selinexor) • Andewei (benmelstobart) • Hetronifly (serplulimab)